131110-76-4

Basic information

• Product Name: Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate
• Synonyms: Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate;D-N-Benzylserine Methyl Ester;N-(phenylmethyl)-D-Serinemethyl ester;Bzl-D-Ser-OMe
• CAS NO: 131110-76-4
• Molecular Formula: C₁₁H₁₅NO₃
• Molecular Weight: 209.243
• Mol File: 131110-76-4.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 351.127°C at 760 mmHg
• Flash Point: 166.156°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate(131110-76-4)
• EPA Substance Registry System: Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate(131110-76-4)

Safety Data

• Hazardous Substances Data: 131110-76-4(Hazardous Substances Data)

Usage

General Description

Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate is a chemical compound that belongs to the family of methyl esters. It contains a chiral center, denoted as (R), indicating the stereochemistry of the molecule. The compound consists of a benzylamino group attached to a 3-hydroxypropanoate moiety. It is commonly used in organic synthesis and pharmaceutical research, where its chiral nature makes it a valuable building block for the preparation of various biologically active compounds. This chemical has potential applications in the development of new drugs and in the study of biochemical processes.

InChI:InChI=1/C11H15NO3/c1-15-11(14)10(8-13)12-7-9-5-3-2-4-6-9/h2-6,10,12-13H,7-8H2,1H3/t10-/m1/s1

Upstream product

• 2104-89-4 D-serine methyl ester 
• 100-52-7 benzaldehyde 
• 5874-57-7 R-(-)-serine methyl ester hydrochloride 
• 40216-75-9 (R)-3-Hydroxy-2-{[1-phenyl-meth-(E)-ylidene]-amino}-propionic acid methyl ester 

Downstream Products

• 199786-65-7 N-benzyl-N-carbobenzyloxy-O-tert-butyldimethylsilyl-D-serinal 
• 199786-66-8 Benzyl-[(1R,2S)-1-(tert-butyl-dimethyl-silanyloxymethyl)-2-hydroxy-pent-4-enyl]-carbamic acid benzyl ester 
• 1365059-89-7 N-methyl-N-benzyl-D-serine methyl ester 
• 1311981-47-1 dimethyl Nα-tert-butoxycarbonyl-Nα'-benzyl-τ-L-histidino-D-alaninate 
• 1311981-39-1 methyl 4R,3-benzyl-2,2-dioxo-1,2,3-oxathiazolidine-4-carboxylate 
• 1258937-54-0 4-allyl 1-[(2R)-2-(benzylamino)-3-methoxy-3-oxopropyl] N-(tert-butoxycarbonyl)-L-aspartate 
• 929048-00-0 (7R,9aR)-7-(hydroxymethyl)-8-(phenylmethyl)hexahydropyrazino[2,1-c][1,4]oxazine-6,9-dione 
• 144001-46-7 1-benzyl-2α-(hydroxymethyl)-4α-nitro-3β-pyrrolidineacetic acid ethyl ester 
• 144001-46-7 1-benzyl-2α-(hydroxymethyl)-4β-nitro-3β-pyrrolidineacetic acid ethyl ester 
• 144001-49-0 1-benzyl-2α-<<<(1,1-dimethylethyl)dimethylsilyl>oxy>methyl>-4β-<(1,3-dioxolan-2-yl)methyl>-4α-nitro-3β-pyrrolidineacetic acid ethyl ester 
• 144001-48-9 1-benzyl-2α-<<<(1,1-dimethylethyl)dimethylsilyl>oxy>methyl>-4β-(hydroxymethyl)-4α-nitro-3β-pyrrolidineacetic acid ethyl ester 

Relevant articles and documents

TETRACYCLIC HETEROARYL COMPOUNDS

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

HIV PROTEASE INHIBITORS

The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Synthesis of histidinoalanine: A comparison of β-lactone and sulfamidate electrophiles

Previous syntheses of histidinoalanine (HAL) have led to mixtures of regioisomers and/or stereoisomers. For example, opening of N-Cbz-d-serine- β-lactone (6) with Boc-l-His-OMe (5) gave a 2:1 mixture of τ- and π-regioisomers. The sulfamidate 10, derived f